Celldex Therapeutics (CLDX) to Release Quarterly Earnings on Monday

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) will likely be announcing its earnings results before the market opens on Monday, February 24th. Analysts expect the company to announce earnings of ($0.73) per share and revenue of $1.31 million for the quarter.

Celldex Therapeutics Stock Down 2.0 %

NASDAQ CLDX traded down $0.46 on Thursday, reaching $22.59. The company had a trading volume of 325,742 shares, compared to its average volume of 948,595. The company's fifty day moving average is $24.47 and its 200 day moving average is $29.49. Celldex Therapeutics has a 52-week low of $20.91 and a 52-week high of $53.18. The stock has a market capitalization of $1.50 billion, a P/E ratio of -8.79 and a beta of 1.60.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Wednesday, January 29th. HC Wainwright reiterated a "buy" rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Finally, UBS Group assumed coverage on Celldex Therapeutics in a research note on Thursday, February 13th. They issued a "buy" rating and a $44.00 target price on the stock. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $60.22.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.